Charles Schwab Investment Management Inc. Boosts Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Charles Schwab Investment Management Inc. raised its position in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 9.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 316,134 shares of the company’s stock after purchasing an additional 26,870 shares during the period. Charles Schwab Investment Management Inc. owned about 0.60% of Stoke Therapeutics worth $3,885,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in STOK. Lynx1 Capital Management LP grew its stake in Stoke Therapeutics by 40.3% in the 2nd quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company’s stock valued at $70,052,000 after acquiring an additional 1,488,371 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Stoke Therapeutics by 426.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company’s stock valued at $18,741,000 after purchasing an additional 1,123,500 shares in the last quarter. Logos Global Management LP purchased a new stake in shares of Stoke Therapeutics in the second quarter valued at about $14,186,000. Marshall Wace LLP grew its position in shares of Stoke Therapeutics by 550.1% in the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company’s stock valued at $15,686,000 after purchasing an additional 982,451 shares during the last quarter. Finally, Millennium Management LLC increased its stake in shares of Stoke Therapeutics by 528.6% during the 2nd quarter. Millennium Management LLC now owns 289,067 shares of the company’s stock worth $3,905,000 after purchasing an additional 243,083 shares in the last quarter.

Stoke Therapeutics Trading Down 2.1 %

NASDAQ STOK opened at $12.06 on Friday. The business’s 50-day moving average price is $12.49 and its 200 day moving average price is $13.64. The company has a market capitalization of $638.82 million, a PE ratio of -5.74 and a beta of 0.95. Stoke Therapeutics, Inc. has a twelve month low of $4.09 and a twelve month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The firm had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $3.46 million. Equities analysts predict that Stoke Therapeutics, Inc. will post -2.03 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Leerink Partners initiated coverage on Stoke Therapeutics in a research note on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Leerink Partnrs raised shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $20.83.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $12.07, for a total value of $120,700.00. Following the sale, the insider now owns 51,277 shares of the company’s stock, valued at $618,913.39. The trade was a 16.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Edward M. Md Kaye sold 6,786 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $88,150.14. Following the completion of the transaction, the chief executive officer now owns 61,885 shares of the company’s stock, valued at approximately $803,886.15. This represents a 9.88 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,000,349 shares of company stock worth $28,031,296. 11.30% of the stock is owned by corporate insiders.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.